Androgen receptor mutation

US10011874B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Giordano Caponigro · Salt Lake City, US
• Vesselina Cooke · Newton, US
• Scott Delach · Cambridge, US
• Joshua Korn · Cambridge, US
• Manav Korpal · Winchester, US
• Wenlai Zhou · Cambridge, US
• Ping Zhu · Boxborough, US

Key dates

• Filing date: Feb 24, 2014
• Grant date: Jul 3, 2018
• Expiry date: Aug 10, 2034

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compositions and methods are provided for diagnosis, prognosis and treatment of AR-related diseases, such as prostate diseases, such as prostate cancer, breast cancer, and many other diseases. In particular, a novel and clinically relevant mutation at position 877 of the androgen receptor (AR) has been identified. Drug sensitivity can be predicted and therapeutic regimens can be planned on the basis of the presence or absence of this mutation. Polypeptides comprising, antibodies to, and polynucleotides encoding the mutant AR can be used to identity novel treatments. A double mutation in AR at positions 742 and 878 is also shown to be useful for patient stratification.